



# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER OF PATENTS AND TRADEMARKS  
Washington, D.C. 20231  
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/766,362	01/19/2001	Solomon S. Steiner	PDC 119	8907

23579 7590 03/12/2003

PATREA L. PABST  
HOLLAND & KNIGHT LLP  
SUITE 2000, ONE ATLANTIC CENTER  
1201 WEST PEACHTREE STREET, N.E.  
ATLANTA, GA 30309-3400

EXAMINER
----------

SHEIKH, HUMERA N

ART UNIT	PAPER NUMBER
----------	--------------

1615

DATE MAILED: 03/12/2003

Please find below and/or attached an Office communication concerning this application or proceeding.

**Office Action Summary**

Application No.

09/766,362

Applicant(s)

STEINER ET AL.

Examiner

Humera N. Sheikh

Art Unit

1615

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

**Period for Reply**

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133).
- Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

**Status**

- 1) ☒ Responsive to communication(s) filed on 22 January 2003 (paper no. 15).
- 2a) ☐ This action is **FINAL**.                      2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

**Disposition of Claims**

- 4) ☒ Claim(s) 1-19 is/are pending in the application.
- 4a) Of the above claim(s) \_\_\_\_\_ is/are withdrawn from consideration.
- 5) ☐ Claim(s) \_\_\_\_\_ is/are allowed.
- 6) ☒ Claim(s) 1-19 is/are rejected.
- 7) ☐ Claim(s) \_\_\_\_\_ is/are objected to.
- 8) ☐ Claim(s) \_\_\_\_\_ are subject to restriction and/or election requirement.

**Application Papers**

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on \_\_\_\_\_ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.
- Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
- 11) ☐ The proposed drawing correction filed on \_\_\_\_\_ is: a) ☐ approved b) ☐ disapproved by the Examiner.
- If approved, corrected drawings are required in reply to this Office action.
- 12) ☐ The oath or declaration is objected to by the Examiner.

**Priority under 35 U.S.C. §§ 119 and 120**

- 13) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some \* c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
2. ☐ Certified copies of the priority documents have been received in Application No. \_\_\_\_\_.
3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).
- \* See the attached detailed Office action for a list of the certified copies not received.
- 14) ☐ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).
- a) ☐ The translation of the foreign language provisional application has been received.
- 15) ☐ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.

**Attachment(s)**

- 1) ☒ Notice of References Cited (PTO-892)                      4) ☐ Interview Summary (PTO-413) Paper No(s). \_\_\_\_\_
- 2) ☐ Notice of Draftsperson's Patent Drawing Review (PTO-948)                      5) ☐ Notice of Informal Patent Application (PTO-152)
- 3) ☐ Information Disclosure Statement(s) (PTO-1449) Paper No(s) \_\_\_\_\_                      6) ☐ Other: \_\_\_\_\_

## **DETAILED ACTION**

### **Status of the Application**

Acknowledgement is made of the receipt of the Request for Extension of Time (3 months) filed 11/13/02, the Notice of Appeal filed 11/13/02 and the Request for Extension of Time (1 month), the Request for Continued Examination under Rule 1.114 and the Preliminary Amendment all filed 01/22/03.

Claims 1-19 are pending. Claims 1, 7 and 14 have been amended. Claims 1-19 are rejected.

### ***Claim Rejections - 35 USC § 112***

The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

Claims 1-19 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

Claim 1, line 5 recites the limitation, "the dry powder form comprising microparticles formed of the *drug and a polymer or diketopiperazine*". It is unclear what the applicant is intending to convey since the limitation, "drug and a polymer or diketopiperazine" can be interpreted in three distinct ways. The first interpretation can

Art Unit: 1615

include microparticles formed of the *drug and a polymer*, the second interpretation can be: microparticles formed of the *drug and diketopiperazine* and the third interpretation can be: microparticles formed of the *diketopiperazine* alone. This indefiniteness also applies to independent claims 7 and 14. Clarification is requested.

### ***Claim Rejections - 35 USC § 102***

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless –

(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

**Claims 1-4, 6-11 and 13-17 and 19 are rejected under 35 U.S.C. 102(b) as being anticipated by Illum (US Pat. No. 5,690,954).**

Illum discloses a drug delivery system for nasal administration of an active drug wherein the drug delivery system comprises microsphere particles formed of an active drug and polymeric materials whereby the composition is administered in the form of a dry powder having a particle size of from about 10 microns to about 100 microns (see reference column 4, lines 5-35); (col. 5, line 14 through col. 6, line 28).

***Claim Rejections - 35 USC § 103***

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

The factual inquiries set forth in *Graham v. John Deere Co.*, 383 U.S. 1, 148 USPQ 459 (1966), that are applied for establishing a background for determining obviousness under 35 U.S.C. 103(a) are summarized as follows:

1. Determining the scope and contents of the prior art.
2. Ascertaining the differences between the prior art and the claims at issue.
3. Resolving the level of ordinary skill in the pertinent art.
4. Considering objective evidence present in the application indicating obviousness or nonobviousness.

**Claims 5, 12 and 18 are rejected under 35 U.S.C. 103(a) as being unpatentable over Illum (US Pat. No. 5,690,954) in view of Camden (US Pat. No. 6,136,835).**

Illum, as discussed above, teaches a drug delivery system for nasal administration of an active drug wherein the drug delivery system comprises microsphere particles formed of an active drug and polymeric materials whereby the composition is administered in the form of a dry powder having a particle size of from about 10 microns to about 100 microns (see reference column 4, lines 5-35); (col. 5, line 14 through col. 6, line 28).

The particulate drug delivery system for administration of an active drug comprises microspheres, which include an effective amount of the active drug and an absorption enhancing material associated with each microsphere which enhances passage of the active drug through a membrane and increases the bioavailability of the active drug (claim 1).

Preferably, the particles are administered in the form of a powder by spraying and have bioadhesive properties. The microspheres should be of a size between 10 and 100 microns and prepared from a biocompatible material. Suitable materials include, starch, gelatin, casein, dextrans, albumin, collagen, alginates, polyvinyl acetate, etc (col. 6, lines 13-28).

Illum teaches that the drug to be administered to a mucosal surface such as the nose, eye, etc., can be administered as a powder and can also be administered in the form of a colloidal particle comprising a microsphere system. The advantage of using bioadhesive microsphere systems for administration to the mucosal surface is that such systems allow a longer period of contact, especially if the microspheres are slowly degrading. This is particularly true for the nasal administration of drugs contained in microspheres produced from natural materials such as albumin, gelatin and starch (col. 5, line 14-26).

Additional suitable drugs that can be used are anti-inflammatory agents, vasoconstrictors and antihistaminic agents, such as diphenhydramine hydrochloride, chlorpheniramine maleate and clemastine. The microspheres can be administered via the nasal route using a nasal insufflator device (col. 8, line 44 through col. 9, line 60).

Art Unit: 1615

Illum teaches microspheres having a particle size of between 10 and 100 microns. The instant claims require an average particle size of between 10 and 20 microns. The range taught by the prior art, is a broader range, which reads on the applicant's claimed range of 10-20 microns.

Illum's patent is deficient only in the sense that it does not explicitly teach a drug which is formulated in a diketopiperazine formulation.

**Camden** teaches a method for the treatment of viral infections comprising a diketopiperazine derivative in combination with another compound or derivative, wherein the composition can be suitable for nasal administration and comprises a powder having a particle size of less than about 100 microns, preferably less than about 50 microns (see reference col. 13, lines 20-32); (col. 16, line 61 through col. 17, line 4).

Therefore, it would have been obvious to one of ordinary skill in the art at the time the invention was made to use the teachings of Camden within the teachings of Illum because Camden explicitly teaches the use of a diketopiperazine derivative in the form of a powder, suitable for nasal administration wherein the powder has a particle size of less than about 100 microns and more preferably, less than about 50 microns and Illum teaches a particulate drug delivery system comprising particles having a particle size of between 10 and 100 microns whereby the composition can be nasally administered and in the form of a dry powder. The expected result would be an improved particulate formulation for nasal application that provides suitable drug retention in the nasal region.

### Correspondence

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Humera N. Sheikh whose telephone number is (703) 308-4429. The examiner can normally be reached on Monday through Friday from 7:00A.M. to 4:30P.M.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Thurman Page, can be reached on (703) 308-2927. The fax phone number for the organization where this application or proceeding is assigned is (703) 308-4556.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is (703) 308-1235.

*hns*  
March 07, 2003

THURMAN K. PAGE  
SUPERVISORY PATENT EXAMINER  
TECHNOLOGY CENTER 1600  
